JP7595055B2 - ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物 - Google Patents

ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物 Download PDF

Info

Publication number
JP7595055B2
JP7595055B2 JP2022500099A JP2022500099A JP7595055B2 JP 7595055 B2 JP7595055 B2 JP 7595055B2 JP 2022500099 A JP2022500099 A JP 2022500099A JP 2022500099 A JP2022500099 A JP 2022500099A JP 7595055 B2 JP7595055 B2 JP 7595055B2
Authority
JP
Japan
Prior art keywords
alkyl
mmol
compound
cancer
reaction mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022500099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539256A5 (https=
JPWO2021003157A5 (https=
JP2022539256A (ja
Inventor
スペリー，サミュエル
シャン，アラン・エックス
アーンスト，ジャスティン・ティー
ライヒ，ジークフリート・エイチ
スプレンゲラー，ポール・エイ
シャガフィ，マイク
ミヘルス，テオ
ニレウスキ，クリスチャン
トラン，チン・ベト
パッカード，ガーリック・ケネス
グラブス，アラン
ウルカラン，カヴェリ
ムカイヤマ，タカスケ
Original Assignee
エフェクター・セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフェクター・セラピューティクス，インコーポレーテッド filed Critical エフェクター・セラピューティクス，インコーポレーテッド
Publication of JP2022539256A publication Critical patent/JP2022539256A/ja
Publication of JP2022539256A5 publication Critical patent/JP2022539256A5/ja
Publication of JPWO2021003157A5 publication Critical patent/JPWO2021003157A5/ja
Application granted granted Critical
Publication of JP7595055B2 publication Critical patent/JP7595055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022500099A 2019-07-02 2020-06-30 ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物 Active JP7595055B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02
US62/869,662 2019-07-02
PCT/US2020/040299 WO2021003157A1 (en) 2019-07-02 2020-06-30 Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds

Publications (4)

Publication Number Publication Date
JP2022539256A JP2022539256A (ja) 2022-09-07
JP2022539256A5 JP2022539256A5 (https=) 2023-06-16
JPWO2021003157A5 JPWO2021003157A5 (https=) 2023-06-16
JP7595055B2 true JP7595055B2 (ja) 2024-12-05

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500099A Active JP7595055B2 (ja) 2019-07-02 2020-06-30 ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物

Country Status (15)

Country Link
US (2) US11286268B1 (https=)
EP (1) EP3994139A1 (https=)
JP (1) JP7595055B2 (https=)
KR (1) KR20220061945A (https=)
CN (1) CN114269756B (https=)
AR (1) AR119339A1 (https=)
AU (1) AU2020299362B2 (https=)
BR (1) BR112021026682A2 (https=)
CA (2) CA3085255A1 (https=)
CL (1) CL2021003573A1 (https=)
IL (1) IL289456A (https=)
PY (1) PY2031844A (https=)
TW (1) TWI748541B (https=)
UY (1) UY38773A (https=)
WO (1) WO2021003157A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
JP2023554521A (ja) 2020-12-22 2023-12-27 ファイザー・インク Ｅｉｆ４ｅ阻害剤の固体形態
JP2025539263A (ja) * 2022-11-10 2025-12-04 リボメトリックス，インコーポレイティド ｅＩＦ４Ｅ阻害剤としての化合物及び組成物、ならびにそれらの使用
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為ｅＩＦ４Ｅ抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523674A (ja) 2007-04-11 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼ阻害剤としての使用のための３−ヒドロキナゾリン−４−オン誘導体
JP2011520969A (ja) 2008-05-19 2011-07-21 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用
WO2014179237A1 (en) 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2015120350A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523674A (ja) 2007-04-11 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼ阻害剤としての使用のための３−ヒドロキナゾリン−４−オン誘導体
JP2011520969A (ja) 2008-05-19 2011-07-21 シェーリング コーポレイション 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用
WO2014179237A1 (en) 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIRI,R.S. et al.，Synthesis and evaluation of quinazolinone derivatives as inhibitors of NF-κB, AP-1 mediated transcription and eIF-4E mediated translational activation: Inhibitors of multi-pathways involve in cancer，European Journal of Medicinal Chemistry，2010年，Vol.45, No.9，pp.3558-3563，DOI：10.1016/j.ejmech.2010.04.038
ROERSCH,F. et al.，Structure-Activity Relationship of Nonacidic Quinazolinone Inhibitors of Human Microsomal Prostaglandin Synthase 1 (mPGES 1)，Journal of Medicinal Chemistry，2012年，Vol.55, No.8，pp.3792-3803，DOI： 10.1021/jm201687d

Also Published As

Publication number Publication date
CN114269756A (zh) 2022-04-01
CA3188446A1 (en) 2021-01-07
AU2020299362A1 (en) 2022-02-24
PY2031844A (es) 2021-04-19
TWI748541B (zh) 2021-12-01
CA3085255A1 (en) 2021-01-02
WO2021003157A1 (en) 2021-01-07
IL289456A (en) 2022-02-01
JP2022539256A (ja) 2022-09-07
KR20220061945A (ko) 2022-05-13
AR119339A1 (es) 2021-12-09
UY38773A (es) 2021-01-29
BR112021026682A2 (pt) 2022-03-15
CL2021003573A1 (es) 2022-08-12
US11286268B1 (en) 2022-03-29
TW202115058A (zh) 2021-04-16
CN114269756B (zh) 2024-05-14
EP3994139A1 (en) 2022-05-11
US20230108594A1 (en) 2023-04-06
AU2020299362B2 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
JP7595055B2 (ja) ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物
US10112955B2 (en) Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
TWI762579B (zh) 六氫吡啶經取代之ＭｎＫ抑制劑及其相關方法
US9669031B2 (en) MNK inhibitors and methods related thereto
US11014926B2 (en) Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2
US9458172B2 (en) Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220714

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241125

R150 Certificate of patent or registration of utility model

Ref document number: 7595055

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150